Literature DB >> 21115423

Deciphering the role of PI3K/Akt/mTOR pathway in breast cancer biology and pathogenesis.

Priscilla F McAuliffe1, Funda Meric-Bernstam, Gordon B Mills, Ana M Gonzalez-Angulo.   

Abstract

The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway mediates multiple cellular functions critical to tumor initiation, progression, and outcomes, including growth and proliferation, metabolism, motility, migration, invasion, angiogenesis, survival, and autophagy. Tight regulation of this pathway is paramount to ensure that multiple cellular inputs are integrated for appropriate cellular outcomes. Frequent deregulation and aberrations of this pathway have been implicated in breast cancer development and progression. This review focuses on the biology of this pathway and its role in breast cancer pathogenesis. The role of therapies directed at targeting mTOR in the PI3K/Akt/mTOR pathway, which are currently being evaluated in clinical trials, will also be reviewed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21115423     DOI: 10.3816/CBC.2010.s.013

Source DB:  PubMed          Journal:  Clin Breast Cancer        ISSN: 1526-8209            Impact factor:   3.225


  52 in total

1.  Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents.

Authors:  Prasanth Ganesan; Stacy Moulder; J Jack Lee; Filip Janku; Vicente Valero; Ralph G Zinner; Aung Naing; Siqing Fu; Apostolia M Tsimberidou; David Hong; Bettzy Stephen; Philip Stephens; Roman Yelensky; Funda Meric-Bernstam; Razelle Kurzrock; Jennifer J Wheler
Journal:  Mol Cancer Ther       Date:  2014-09-24       Impact factor: 6.261

2.  Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer.

Authors:  Ana M Gonzalez-Angulo; Huiqin Chen; Meghan S Karuturi; Mariana Chavez-MacGregor; Spyrus Tsavachidis; Funda Meric-Bernstam; Kim-Anh Do; Gabriel N Hortobagyi; Patricia A Thompson; Gordon B Mills; Melissa L Bondy; George R Blumenschein
Journal:  Cancer       Date:  2012-06-26       Impact factor: 6.860

3.  INPP4B overexpression enhances the antitumor efficacy of PARP inhibitor AG014699 in MDA-MB-231 triple-negative breast cancer cells.

Authors:  Ying Sun; Huan Ding; Xinguang Liu; Xiaoqing Li; Li Li
Journal:  Tumour Biol       Date:  2014-01-14

Review 4.  A New Linkage between the Tumor Suppressor RKIP and Autophagy: Targeted Therapeutics.

Authors:  Yuhao Wang; Benjamin Bonavida
Journal:  Crit Rev Oncog       Date:  2018

5.  Exercise increases mTOR signaling in brain regions involved in cognition and emotional behavior.

Authors:  Brian A Lloyd; Holly S Hake; Takayuki Ishiwata; Caroline E Farmer; Esteban C Loetz; Monika Fleshner; Sondra T Bland; Benjamin N Greenwood
Journal:  Behav Brain Res       Date:  2017-01-24       Impact factor: 3.332

6.  EBP50 inhibits the migration and invasion of human breast cancer cells via LIMK/cofilin and the PI3K/Akt/mTOR/MMP signaling pathway.

Authors:  Hongli Li; Baogang Zhang; Yuqing Liu; Chonggao Yin
Journal:  Med Oncol       Date:  2014-08-14       Impact factor: 3.064

7.  Differential proteomic analysis of pathway biomarkers in human breast cancer by integrated bioinformatics.

Authors:  Liu Fu-Jun; Jin Shao-Hua; Shen Xiao-Fang
Journal:  Oncol Lett       Date:  2012-08-24       Impact factor: 2.967

Review 8.  Interactions between tumor cells and microenvironment in breast cancer: a new opportunity for targeted therapy.

Authors:  Shreya Mitra; Katherine Stemke-Hale; Gordon B Mills; Sofie Claerhout
Journal:  Cancer Sci       Date:  2012-01-30       Impact factor: 6.716

9.  Increased expression of CYP4Z1 promotes tumor angiogenesis and growth in human breast cancer.

Authors:  Wei Yu; Hongyan Chai; Ying Li; Haixia Zhao; Xianfei Xie; Hao Zheng; Chenlong Wang; Xue Wang; Guifang Yang; Xiaojun Cai; John R Falck; Jing Yang
Journal:  Toxicol Appl Pharmacol       Date:  2012-07-25       Impact factor: 4.219

Review 10.  Role of mTOR inhibition in preventing resistance and restoring sensitivity to hormone-targeted and HER2-targeted therapies in breast cancer.

Authors:  Ingrid Mayer
Journal:  Clin Adv Hematol Oncol       Date:  2013-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.